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Abstract
Background: Fibromyalgia (FM) is a complex long-term condition associated with
chronic widespread pain, fatigue, sleep problems, memory and concentration difficul-
ties and irritable bowel syndrome. Current guidelines for the treatment of FM recom-
mend nonpharmacological interventions.
The Fibromyalgia Self-Management Programme (FSMP) is a nonpharmacological,
multidisciplinary exercise and education group intervention. It aims to provide educa-
tion and teach core skills, enabling those affected by FM to self-manage. The FSMP
is currently codelivered by a multidisciplinary team within a secondary care service.
The aim of this feasibility randomised controlled trial (RCT) is to determine the practi-
cality and acceptability of delivering the FSMP in a community setting, informing a
future RCT of effectiveness.
Methods: The feasibility RCT aims to recruit 70 people with FM. Participants will be
randomised to either a community FSMP or control arm. All participants will be asked
to complete six patient-reported outcome measures and one health economics ques-
tionnaire on three occasions; baseline, 6 weeks (end of the intervention) and
6 months. Between 12 and 16 participants and four therapists delivering the FSMP
will be invited to take part in a semi-structured interview to explore their experiences
of the FSMP. Patient participants will be purposively selected based upon key
characteristics.
Analysis: Quantitative data will be analysed descriptively to summarise recruitment
and attendance, participant reported outcomes and health economic data. Semi-
structured interviews will be transcribed, anonymised and inductively coded. The
codes will be grouped into categories and theoretically thematically analysed, com-
paring the results to existing literature.
Trial registration: The trial is registered with ISRCTN registry and was assigned on
29th of April 2020. The registration number is ISRCTN10824225.
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1 | INTRODUCTION
Fibromyalgia (FM) is a complex long-term condition affecting up to
5.4% of the U.K. population (Fayaz, Croft, Langford, Donaldson, &
Jones, 2016; Jones et al., 2015). Common symptoms include chronic
widespread pain, fatigue, stiffness, sleep problems, cognitive dysfunc-
tion and psychological distress (Arnold et al., 2019; Bennett, 2009).
FM is associated with high levels of disability, frequent use of
healthcare resources and loss of workdays (Boonen et al., 2005;
Hughes, Martinez, Myon, Taïeb, & Wessely, 2006; Soni et al., 2019).
There is limited robust evidence for the effectiveness of pharma-
cological treatments for FM (Eich et al., 2012). Current guidelines for
the treatment of FM all recommend nonpharmacological interventions,
of which cognitive behaviour therapy (CBT), aerobic exercise, warm
water therapy, relaxation and patient education are best evidenced
(Fitzcharles et al., 2013; Hughes et al., 2006; Macfarlane et al., 2017;
Nüesch, Häuser, Bernardy, Barth, & Jüni, 2013). In combination with
the pharmacological and nonpharmacological interventions to treat
FM, a common patient goal is to develop the knowledge and skills
needed to independently self-manage their condition.
The evidence for self-management interventions are compelling.
They have been shown to improve both physical symptoms and func-
tion, participant engagement, self-efficacy and mood and reduce health
service costs in a number of long-term conditions (Kennedy
et al., 2007; Newman, Steed, &Mulligan, 2004; Schulman-Green, Jaser,
Park, &Whittemore, 2016). Previous research on FM self-management
within a community setting found short-term improvement in severity
of FM symptoms, improvement in self-efficacy to manage symptoms
of pain, decreased fatigue and a reduction in General Practitioner
(GP) FM related contacts (Hammond & Freeman, 2006).
Allied health professionals at the Royal National Hospital for
Rheumatic Diseases, Royal United Hospitals Bath NHS Foundation
Trust (RUHB), designed the Fibromyalgia Self-Management Pro-
gramme (FSMP), a nonpharmacological, multidisciplinary exercise and
education group intervention. The FSMP has been delivered by the
RUHB for over 10 years. The patient attendees are regularly asked for
feedback to inform service improvements. The main aims of the FSMP
are to provide condition-specific, patient-centred, education and exer-
cise advice and to support the development of core self-management
skills for those affected by FM. The FSMP comprises one 2.5-hour
weekly session over six consecutive weeks. Core components include
education about FM, sleep hygiene, goal setting, pacing, hydrotherapy
and dietary advice. Participants can access an FM specific gym group
upon completion of the programme.
A recent study (Pearson et al., 2020) mapped the FSMP to
Behaviour Change Taxonomy (Michie et al., 2013) through non-
participatory observation, review of patient and trainer manuals and
semi-structured interviews with patients and health professionals.
The FSMP mapped on to 22 discrete behaviour change techniques,
covering 12 of the 16 main behaviour change areas. Patients
reported making significant changes to their behaviour in terms of
exercise, pacing and sleep and felt more empowered and knowl-
edgeable in relation to FM. Along with FM education, patient
focused goal setting with active involvement from a therapist in
planning to meet identified goals appeared to be key factors that
facilitated behaviour change. The delivery of the intervention in a
group setting was also beneficial with patients sharing, with others,
their experiences of diagnosis and symptom management (Pearson
et al., 2020). The findings also align with the Capability, Opportunity,
Motivation and Behaviour (COM-B) model (Michie, van Stralen, &
West, 2011) which provides an overall theoretical framework to
explain how the intervention works in practice.
To date, the delivery of the FSMP has been within an acute
hospital setting by a team of specialist Rheumatology Occupational
Therapists (OTs) and Physiotherapists (PTs). However, government
plans recommended that the care of adults affected by long-term
conditions is, where possible, transferred from acute hospital envi-
ronments to the community, with an increased investment in com-
munity care (NHS England, 2014; NHS England, 2019). Transferring
delivery of the FSMP to a community setting presents opportunities
to offer specialised care closer to home and determine the clinical
and cost effectiveness of this. Patient partners have been involved
and consulted on all aspect of delivering the FSMP in the commu-
nity. It is also possible that the programme and training of
healthcare professionals will need to be modified for delivery in the
community. For example, Band 6/7 nonspecialist therapists deliver-
ing the programme may not have a rheumatology background and
are likely to have additional training needs.
2 | OBJECTIVES
The aim of this feasibility trial is to determine the practicality and
acceptability of conducting a randomised controlled trial (RCT) to
deliver the FSMP in the community to inform a future trial to test cost
effectiveness. The research question is whether it is feasible to con-
duct an RCT of a community-based FSMP. The specific objectives of
this research are the following:
• explore the ability to train Band 6 PTs and OTs to deliver the
FSMP in the community;
• explore the ability to recruit adults with FM to the trial from pri-
mary care;
• assess feasibility of collecting a range of outcome data and identify
the primary outcome for a future full trial;
• assess the feasibility and acceptability of collecting health eco-
nomic data;
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• determine recruitment rate and sample size calculations to inform
a full trial; and
• understand patient and health professional acceptability of deliver-
ing the FSMP in the community through qualitative interviews.
3 | METHODS: PARTICIPANTS,
INTERVENTIONS AND OUTCOMES
3.1 | Trial design
The feasibility study will be a multicentre study with a nested qualita-
tive evaluation. Participants will be randomly allocated to either the
FSMP or the control arm using a parallel 1:1 study design. The
randomised sequences list will be conducted by the Research and
Development (R&D) team at the RUHB. To preserve concealment, for
each cohort, a list of nonidentifiable participant ID numbers will be
sent to the R&D team who will allocate participants to either the inter-
vention or the control arm of the feasibility trial according to the
randomisation sequence associated with the ID. Randomisation will be
stratified by sites. The R&D team will not have any contact with the
participants and no access to confidential and clinical data. Following
randomisation, the R&D team will inform the research team and the
research associate (RA) will inform participants of their allocation.
Participants in the intervention arm will be attending the FSMP
and therefore participant blinding is not possible. The therapists
directly involved with delivering the FSMP are also unblinded. Out-
comes will be participant self-reported; however, the quantitative
data analyst will be blinded to participant allocation.
Participants will be entitled to withdraw from the intervention at
any point, and this will not affect their future care.
3.2 | Trial population
The feasibility trial will be conducted across two community provider
sites in the United Kingdom.
Inclusion criteria are adults aged 18 years and over with a con-
firmed diagnosis of FM according to the American College of Rheuma-
tology (2016) diagnostic criteria (Wolfe et al., 2016), willing to take part
in a group-based intervention and able to travel to attend the group
sessions. Exclusion criteria are those under 18 years of age, diagnosed
with rheumatoid arthritis, Generalised Anxiety Disorder Questionnaire
(GAD-7) score above 15, previously attended the RUHB FSMP or pain
management programme, needs a carer to attend the FSMP in the
community or needs an interpreter to communicate in English.
3.3 | Identification of potential participants and
recruitment
In the trial set-up period, selected general practices will be sent a
study information pack which will provide an overview of the study
and trial processes. The practice manager at consenting sites will be
asked to conduct a database search for patients diagnosed with FM
using pre-identified codes. Once the practice has identified potential
trial participants, a member of the practice team will screen for those
participants who are not eligible or unsuitable (for example, recently
bereaved or under investigation). To invite the identified participants
to take part in the study, the research team will supply the participat-
ing GP sites with a patient information pack.
The pack will include an invitation letter from the GP, a
detailed participant information leaflet (PIL), the contact details of
the research team, a reply slip and prepaid return envelope. The
GP team will send out invitations by letter to identified potential
participants. Those participants who respond and are willing to par-
ticipate in the feasibility trial will be asked to return a reply slip in
a prepaid envelope or alternatively they can telephone or e-mail
the research team. They will then be screened over the telephone
by the chief investigator (CI) (JP) for further eligibility criteria
including GAD score, previous attendance at the RUHB FSMP or
pain management programme and requirement of a carer to
enable attendance at the FSMP or an interpreter to communicate
in English.
Once eligibility to the study has been established, the CI will dis-
cuss the PIL with the potential participant to ensure they fully under-
stand the study and verbal consent to take part in the trial will be
obtained. Full written consent will be obtained when the participant
sends their signed consent form to the research team. The consent
form will detail the intent to publish any findings.
In order to refine the delivery and fidelity of the intervention, four
courses will be delivered at two selected community sites in Bristol
and Wiltshire (two courses per site) and include eight to 12 patients
on each course. The trial aims to recruit a total sample size of 70 par-
ticipants, 35 in each arm, to account for loss-to-follow, missing data
and estimate parameters such as the participation or completion rates
and those required to derive the sample size for the main trial, with
enough precision (Figure 1).
3.4 | Interventions
3.4.1 | Fibromyalgia Self-Management Programme
The intervention consists of a 6-week, condition-specific, group pro-
gramme delivered by a PT and an OT. The FSMP comprises one
2.5-hour weekly group session over six consecutive weeks. Each
week the course will focus on supporting the development of indi-
vidual self-management skills by increasing knowledge and under-
standing of the condition, medication, goal setting, pacing, dietary
advice, sleep hygiene, relaxation and exercise advice. The gentle
exercise sessions are optional; participants can partake or observe.
Participants will receive a booklet containing information on the
content of the programme, links to relevant resources and
worksheets. The participants can take notes, complete the
worksheets and keep the booklet when the programme finishes.
Participants in the intervention arm will continue to receive usual
care from their GP throughout the trial.
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3.4.2 | Control arm
Participants allocated to the control arm will continue to receive usual
care from their GP. Once data collection is complete, participants
randomised to the control arm will be sent out an FM information
leaflet. The leaflet will provide information on FM, current treatments
and information about local support groups.
Any adverse events that occur will be reported to the CI and
recorded. Any serious adverse events will be reported within 24 h of
discovery and to the Research Ethics Committee where appropriate.
The CI must also notify the sponsor and provide a summary report to
the Steering Group Committees.
3.5 | Data collection
Several different outcomes will be investigated in this feasibility
study; those that are relevant to the feasibility study and additional
measures needed to design a future definitive trial. All clinical out-
come measures will be patient-reported. Participants randomised to
the intervention arm will return the outcome measures by post at
baseline and 6 months but complete the 6-week outcome measures
on-site at the end of the 6-week intervention. Those in the control
arm will be sent the outcome measures by post for all three
timepoints. Following advice from patient partners, data will not be
collected at additional time points to minimise participant burden.
F IGURE 1 Participant timeline
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The primary outcomes that are of particular relevance for feasibil-
ity of a future trial include number of patients coded as FM in primary
care, percentage of FM patients deemed eligible, recruitment to the
feasibility trial as a percentage of those contacted, number of
analysable completed patient-reported questionnaires, attendance at
the FSMP and number of patients who drop out of the FSMP.
To identify a suitable and feasible primary outcome measure for
the definitive trial, the research team will collect a range of FM symp-
tom based, quality of life (QoL) and self-management specific out-
come measures. To assess the impact of FM symptoms, the Revised
Fibromyalgia Impact Questionnaire (FIQR), a validated outcome mea-
sure to evaluate FM, will be included (Bennett et al., 2009).
As fatigue is a significant symptom that people affected by FM
find burdensome (Humphrey et al., 2010; Wolfe, Hawley, &
Wilson, 1996) the Chalder Fatigue Questionnaire will be used
(Chalder et al., 1993), which has previously been used in the FM pop-
ulation (Naschitz et al., 2005). To monitor changes to QoL, the SF-36
will be used which has been validated for use in Primary Care (Brazier
et al., 1992). The EQ-5D-5L will also be used to measure QoL
(Herdman et al., 2011).
As self-efficacy can predict changes in self-management
related health behaviours and increased levels of self-efficacy are
closely linked with effective self-management of FM (Beal,
Stuifbergen, & Brown, 2009; Burckhardt, 2005), arthritis self-efficacy
outcome data will also be collected (Lorig, Chastain, Ung, Shoor, &
Holman, 1989). The Arthritis Self-Efficacy Scale-8 (AES-8) will be
used as it is a reliable and valid measure for FM (Brady, 2011;
Mueller, Hartmann, Mueller, & Eich, 2003). To see whether any
changes in sleep occur, Jenkins Sleep Scale data will be collected
(Jenkins, Stanton, Niemcryk, & Rose, 1988; Crawford, Piault, Lai, &
Sarzi-Puttini, 2010).
To assess the feasibility of collecting health economic data, the
Client Service Receipt Inventory (CSRI) will be adapted for FM to col-
lect health and social care use (Beecham & Knapp, 2001; Curtis &
Burns, 2018). In addition, a comprehensive medical records review will
be conducted. This health economic data will be collected by the RA
who will attend each participating GP practice and perform an
electronic medical record review of consultations, prescriptions and
onward referrals to other services in the last 6 months (Table 1).
Between 12 and 16 patient participants and four therapists deliv-
ering the programme will be invited to take part in semi-structured
interviews to share their experiences of the FMSP. Patient partici-
pants will be purposively selected based upon key characteristics
including trial site, age, gender, severity of FM and attendance at the
FSMP. The semi-structured interviews will be transcribed, anonymised
and inductively coded. The codes will be grouped into categories and
theoretically thematically analysed, comparing the results to existing
literature.
3.6 | Data management
The CI will ensure confidentiality of participants and ensure the
study adheres to the Data Protection Act (2018). Self-reported
questionnaires and data regarding subjects will be physically kept in
the CI's office in a locked filing cabinet on secure premises at UWE,
accessed by digitally locked corridors and a key-locked door. Access
will only be granted to members of the research team. Electronic
identifiable participant information will be kept on UWE secure
password protected computers and stored securely within an NHS
therapy office at the study sites. Once the intervention has been
completed at the trial sites, the research team will ensure that any
participant identifiable information will be electronically deleted, and
hard copies shredded in accordance with NHS policy. Qualitative
data will be anonymised and managed by the research team. Patient
information and all appropriate documentation will be stored for a
minimum of six years after the completion of the study, in accor-
dance with the Data Protection Act (2018).
All members of the research team will be trained to the appropri-
ate level of good clinical practice standards, to ensure the collection
of good quality data and that the protocol data collection processes
will be followed. The collected quantitative data will be inputted by
the RA, and 10% of the data will be double-checked by another mem-
ber of the research team. The RA will contact research participants for
any missing data. However, to ensure that participants are not over-
burdened, they will be contacted a maximum of three times at each
data collection time point.
4 | ANALYSIS
The collected data will be analysed using qualitative and quantitative
methods.
4.1 | Quantitative data analysis
Quantitative descriptive analysis will include the number and per-
centages of participants approached, recruited and retained in the
study and the completion of the intervention with outcome data.














To assess disabling fatigue in
hospital and community settings
SF-36 Quality of life
EQ-5D-5L Quality of life
Jenkins Sleep Scale Sleep quality
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The final data will also include reasons for nonparticipation, loss to
follow-up, withdrawal, missing data and noncompliance with the
protocol which will be described, with the emphasis on how these
may impact on the full-scale trial. These rates will be also presented
by trial arms to investigate any differences requiring particular
attention in the design of the main trial. Deviations from the
protocol will be recorded and reported by relevant categories to
identify areas requiring particular attention during the design of the
main trial.
Descriptive statistics, including means and standard deviations,
will be used to analyse the patient-reported outcome measures. No
comparison between arms will be conducted. The data complete-
ness of the different outcomes to identify those with the highest
completion rate and candidate measures for the main trial will also
be reported. Health economic data will also be analysed descrip-
tively. The results will inform the selection of the primary outcome
measure and sample size needed for an appropriately powered
full RCT.
No sub-group analyses will be conducted and there will be no
interim analysis.
4.2 | Qualitative data analysis
The qualitative research is underpinned by a qualitative description
approach (Bradshaw, Atkinson, & Doody, 2017). All interviews will be
audio recorded and transcribed verbatim. Each patient participant and
therapist involved in the qualitative study will be given a unique ID
and pseudonym. All transcripts will be read, checked for accuracy and
anonymised for name and place. The qualitative data will then be
transferred and uploaded to NVIVO software (QSR International Pty
Ltd, 2018) where the transcripts will be inductively coded. A selection
of the transcripts will then be doubled coded by two members of the
research team and disagreements recorded. The codes will be
grouped into categories to be theoretically thematically analysed
(Braun & Clarke, 2006; Braun & Clarke, 2019) which will then be com-
pared to existing literature in order to develop a comprehensive
understanding of the acceptability of the intervention in the commu-
nity, feasibility of the RCT and identification of important clinical
outcomes.
A proportion of the FSMP sessions will be recorded for fidelity
purposes. The audio files will be listened to but not transcribed. A
coding framework will be developed by the research team and will be
used as a fidelity assessment tool (Ritchie & Lewis, 2003). The coding
framework will map key areas of the course and the therapist's man-
uals, and the raw audio files will then be coded to the framework.
Data will be analysed exploring whether the therapists delivered the
course in comparison to what is delivered at the RUHB. The results
will help to refine the delivery of the FSMP intervention in the feasi-
bility trial and help to further develop a training package for a
full RCT.
5 | STUDY MONITORING
The overall responsibility for the project will be held by the CI (JP).
Day to day responsibility for the trial will be held by the CI (JP) and
the RA (JC), and a monthly research meeting will occur.
A project steering group meeting will be held four times per
year and will be chaired by the CI (JP). The meeting will be
attended by the full research team, including the patient partners,
and will discuss issues relating to the trial focusing upon recruit-
ment, protocol adherence, data quality, milestones, deliverables and
budget.
To ensure the successful delivery of the feasibility trial, an inde-
pendent trial steering group meeting will be held biannually. The pur-
pose of these meetings is to ensure that the trial is achieving agreed
milestones, deliverables, is on budget and that there are no protocol
violations.
6 | ETHICAL APPROVAL AND
DISSEMINATION
The protection of human subjects in research is of great importance.
This study will adhere to the principles defined in the Declaration of
Helsinki 2008 (Williams, 2008). This study has been reviewed and
approved by Yorkshire & The Humber—South Yorkshire Research
Ethics Committee (18/YH02/63).
To facilitate the impact of this research in practice, it will be
important to provide timely feedback to the stakeholders and
research partners. All stakeholders involved in this trial will receive a
relevant summary of the findings. The results will be disseminated
to academics and clinical leaders locally, and presentations will be
given at local research events, within the local NHS trusts and at
internal seminar series at UWE and the University of Bristol. The
research team intends to present at national conferences, alongside
disseminating results nationally using social media platforms. The
quantitative and qualitative results will be submitted to peer-
reviewed journals.
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